[Utility of global coagulation assays for hemostasis management in hyperclearance-type autoimmune acquired coagulation factor V deficiency].
This case underscores that, even in FV deficiency with a negative inhibitor screen, testing for anti-FV IgG is essential for identifying hyperclearance-type autoimmune FV deficiency (AiFVD), and ex vivo VET and TGT provided actionable assessments of hemostatic capacity and proved useful for guiding management in AiFVD.